Tianjin Development (00882.HK): Lisheng Pharmaceutical's mid-term net profit attributable to shareholders increased by 235.04% year-on-year to 343 million yuan.

China Fortune Financial News App: Tianjin Development (00882.HK) announced the performance of its indirectly non-wholly owned subsidiary Tianjin Lisheng Pharmaceutical Co., Ltd (Lisheng Pharmaceutical) for the six months ended June 30, 2025. The total operating revenue was 732 million RMB, a decrease of 1.76% year-on-year; the net profit attributable to the owners of the parent company was 343 million RMB, an increase of 235.04% year-on-year; and the basic earnings per share were 1.33 yuan.